(DHR) Danaher - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NYSE (USA) | Market Cap: 135.256m USD | Total Return: 6.5% in 12m

Bioprocessing, Measurement, Diagnostics, Filtration, Automation
Total Rating 47
Safety 93
Buy Signal 0.05
Diagnostics & Research
Industry Rotation: +13.4
Market Cap: 135B
Avg Turnover: 731M USD
ATR: 2.59%
Peers RS (IBD): 42.4
Risk 5d forecast
Volatility25.6%
Rel. Tail Risk-6.96%
Reward TTM
Sharpe Ratio0.20
Alpha-18.81
Character TTM
Beta0.587
Beta Downside-0.008
Drawdowns 3y
Max DD37.57%
CAGR/Max DD-0.12
EPS (Earnings per Share) EPS (Earnings per Share) of DHR over the last years for every Quarter: "2021-03": 2.52, "2021-06": 2.46, "2021-09": 2.39, "2021-12": 2.69, "2022-03": 2.76, "2022-06": 2.76, "2022-09": 2.56, "2022-12": 2.87, "2023-03": 2.36, "2023-06": 2.05, "2023-09": 2.02, "2023-12": 2.09, "2024-03": 1.92, "2024-06": 1.72, "2024-09": 1.71, "2024-12": 2.14, "2025-03": 1.88, "2025-06": 0.77, "2025-09": 1.89, "2025-12": 1.68,
EPS CAGR: -12.40%
EPS Trend: -71.5%
Last SUE: -0.05
Qual. Beats: 0
Revenue Revenue of DHR over the last years for every Quarter: 2021-03: 6858, 2021-06: 7218, 2021-09: 7229, 2021-12: 8148, 2022-03: 7688, 2022-06: 7751, 2022-09: 7663, 2022-12: 7134, 2023-03: 5949, 2023-06: 7157, 2023-09: 5624, 2023-12: 6405, 2024-03: 5796, 2024-06: 5743, 2024-09: 5798, 2024-12: 6538, 2025-03: 5741, 2025-06: 5936, 2025-09: 6053, 2025-12: 6838,
Rev. CAGR: -3.08%
Rev. Trend: -60.7%
Last SUE: 0.09
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: DHR Danaher

Danaher Corporation (DHR) is a global manufacturer and marketer of professional, medical, research, and industrial products and services. The company operates across three primary segments: Biotechnology, Life Sciences, and Diagnostics. This diversified structure is common among large-cap healthcare companies.

The Biotechnology segment focuses on bioprocessing technologies, consumables, and services for therapeutic development and manufacturing. This includes cell line development, filtration, and single-use hardware. The Life Sciences segment offers a range of instruments and consumables, such as mass spectrometers, flow cytometry systems, and microscopes, often utilized in academic and pharmaceutical research. The Diagnostics segment provides clinical instruments, consumables, and software for various medical testing areas like immunoassay and hematology, serving hospitals and reference laboratories.

Danahers business model involves both direct sales and a distribution network, leveraging a portfolio of established brands such as Beckman Coulter and Leica Microsystems. The company was founded in 1969 and is headquartered in Washington, D.C. For more in-depth financial analysis of Danaher, consider exploring ValueRay.

Headlines to Watch Out For
  • Biotechnology segment revenue growth drives overall performance
  • Diagnostics segment demand impacts sales and profitability
  • Life Sciences segment innovation expands market share
  • Global healthcare spending influences product adoption
Piotroski VR‑10 (Strict) 7.0
Net Income: 3.61b TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.53 > 1.0
NWC/Revenue: 24.21% < 20% (prev 11.30%; Δ 12.91% < -1%)
CFO/TA 0.08 > 3% & CFO 6.42b > Net Income 3.61b
Net Debt (13.80b) to EBITDA (6.95b): 1.99 < 3
Current Ratio: 1.87 > 1.5 & < 3
Outstanding Shares: last quarter (711.0m) vs 12m ago -3.55% < -2%
Gross Margin: 60.93% > 18% (prev 0.60%; Δ 6.03k% > 0.5%)
Asset Turnover: 30.52% > 50% (prev 30.79%; Δ -0.27% > 0%)
Interest Coverage Ratio: 16.97 > 6 (EBITDA TTM 6.95b / Interest Expense TTM 265.0m)
Altman Z'' 4.26
A: 0.07 (Total Current Assets 12.76b - Total Current Liabilities 6.81b) / Total Assets 83.46b
B: 0.56 (Retained Earnings 46.89b / Total Assets 83.46b)
C: 0.06 (EBIT TTM 4.50b / Avg Total Assets 80.50b)
D: 1.51 (Book Value of Equity 46.69b / Total Liabilities 30.93b)
Altman-Z'' Score: 4.26 = AA
Beneish M -3.18
DSRI: 0.87 (Receivables 3.91b/4.39b, Revenue 24.57b/23.88b)
GMI: 0.98 (GM 60.93% / 59.50%)
AQI: 0.98 (AQ_t 0.78 / AQ_t-1 0.80)
SGI: 1.03 (Revenue 24.57b / 23.88b)
TATA: -0.03 (NI 3.61b - CFO 6.42b) / TA 83.46b)
Beneish M-Score: -3.18 (Cap -4..+1) = AA
What is the price of DHR shares? As of April 08, 2026, the stock is trading at USD 191.01 with a total of 2,930,421 shares traded.
Over the past week, the price has changed by +0.74%, over one month by -3.71%, over three months by -18.74% and over the past year by +6.48%.
Is DHR a buy, sell or hold? Danaher has received a consensus analysts rating of 4.62. Therefore, it is recommended to buy DHR.
  • StrongBuy: 19
  • Buy: 4
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the DHR price?
Analysts Target Price 264.9 38.7%
Danaher (DHR) - Fundamental Data Overview as of 06 April 2026
P/E Trailing = 37.996
P/E Forward = 22.6757
P/S = 5.5054
P/B = 2.5746
P/EG = 1.2381
Revenue TTM = 24.57b USD
EBIT TTM = 4.50b USD
EBITDA TTM = 6.95b USD
Long Term Debt = 18.42b USD (from longTermDebt, last quarter)
Short Term Debt = 2.00m USD (from shortTermDebt, last quarter)
Debt = 18.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.80b USD (from netDebt column, last quarter)
Enterprise Value = 149.06b USD (135.26b + Debt 18.42b - CCE 4.62b)
Interest Coverage Ratio = 16.97 (Ebit TTM 4.50b / Interest Expense TTM 265.0m)
EV/FCF = 28.34x (Enterprise Value 149.06b / FCF TTM 5.26b)
FCF Yield = 3.53% (FCF TTM 5.26b / Enterprise Value 149.06b)
FCF Margin = 21.41% (FCF TTM 5.26b / Revenue TTM 24.57b)
Net Margin = 14.71% (Net Income TTM 3.61b / Revenue TTM 24.57b)
Gross Margin = 60.93% ((Revenue TTM 24.57b - Cost of Revenue TTM 9.60b) / Revenue TTM)
Gross Margin QoQ = 58.00% (prev 58.20%)
Tobins Q-Ratio = 1.79 (Enterprise Value 149.06b / Total Assets 83.46b)
Interest Expense / Debt = 0.30% (Interest Expense 55.0m / Debt 18.42b)
Taxrate = 12.82% (176.0m / 1.37b)
NOPAT = 3.92b (EBIT 4.50b * (1 - 12.82%))
Current Ratio = 1.87 (Total Current Assets 12.76b / Total Current Liabilities 6.81b)
Debt / Equity = 0.35 (Debt 18.42b / totalStockholderEquity, last quarter 52.53b)
Debt / EBITDA = 1.99 (Net Debt 13.80b / EBITDA 6.95b)
Debt / FCF = 2.62 (Net Debt 13.80b / FCF TTM 5.26b)
Total Stockholder Equity = 51.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.49% (Net Income 3.61b / Total Assets 83.46b)
RoE = 6.99% (Net Income TTM 3.61b / Total Stockholder Equity 51.70b)
RoCE = 6.42% (EBIT 4.50b / Capital Employed (Equity 51.70b + L.T.Debt 18.42b))
RoIC = 5.69% (NOPAT 3.92b / Invested Capital 68.97b)
WACC = 7.12% (E(135.26b)/V(153.67b) * Re(8.05%) + D(18.42b)/V(153.67b) * Rd(0.30%) * (1-Tc(0.13)))
Discount Rate = 8.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.38%
[DCF] Terminal Value 81.16% ; FCFF base≈5.27b ; Y1≈5.01b ; Y5≈4.79b
[DCF] Fair Price = 128.6 (EV 104.82b - Net Debt 13.80b = Equity 91.02b / Shares 707.7m; r=7.12% [WACC]; 5y FCF grow -6.55% → 3.0% )
EPS Correlation: -71.52 | EPS CAGR: -12.40% | SUE: -0.05 | # QB: 0
Revenue Correlation: -60.68 | Revenue CAGR: -3.08% | SUE: 0.09 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.87 | Chg7d=-0.008 | Chg30d=-0.008 | Revisions Net=-11 | Analysts=20
EPS current Year (2026-12-31): EPS=8.41 | Chg7d=-0.002 | Chg30d=-0.002 | Revisions Net=+1 | Growth EPS=+7.8% | Growth Revenue=+4.3%
EPS next Year (2027-12-31): EPS=9.10 | Chg7d=+0.001 | Chg30d=+0.001 | Revisions Net=-1 | Growth EPS=+8.2% | Growth Revenue=+5.4%
[Analyst] Revisions Ratio: -0.73 (2 Up / 13 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.4% (Discount Rate 8.1% - Earnings Yield 2.6%)
[Growth] Growth Spread = -1.9% (Analyst 3.5% - Implied 5.4%)
External Resources
Dataroma Stockcircle